Maxim Group Analysts Give Omeros (NASDAQ:OMER) a $32.00 Price Target

Omeros (NASDAQ:OMER) has been given a $32.00 price objective by equities researchers at Maxim Group in a report issued on Friday, TipRanks reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s price objective suggests a potential upside of 73.82% from the company’s previous close.

A number of other analysts have also recently commented on OMER. BidaskClub raised shares of Omeros from a “sell” rating to a “hold” rating in a research report on Tuesday, July 30th. Wedbush reaffirmed a “neutral” rating and set a $18.00 price target on shares of Omeros in a research report on Monday, July 15th. ValuEngine raised shares of Omeros from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Cantor Fitzgerald assumed coverage on shares of Omeros in a research report on Monday, May 6th. They set an “overweight” rating and a $26.00 price target on the stock. Finally, Zacks Investment Research raised shares of Omeros from a “sell” rating to a “hold” rating in a research report on Saturday. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Omeros currently has an average rating of “Buy” and a consensus price target of $25.80.

NASDAQ OMER traded up $0.16 on Friday, reaching $18.41. The company had a trading volume of 929,137 shares, compared to its average volume of 522,710. The firm has a market cap of $906.63 million, a price-to-earnings ratio of -8.29 and a beta of 2.98. Omeros has a fifty-two week low of $10.30 and a fifty-two week high of $27.00. The business has a 50 day moving average price of $15.55.

Omeros (NASDAQ:OMER) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.44) by $0.15. The company had revenue of $26.80 million during the quarter, compared to analyst estimates of $25.33 million. The business’s revenue for the quarter was up 1476.5% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.70) earnings per share. As a group, equities research analysts expect that Omeros will post -1.68 earnings per share for the current fiscal year.

Hedge funds have recently added to or reduced their stakes in the company. Aperio Group LLC bought a new position in shares of Omeros during the 2nd quarter worth about $49,000. Advisory Services Network LLC bought a new position in shares of Omeros during the 1st quarter worth about $69,000. Legal & General Group Plc boosted its position in shares of Omeros by 12.7% during the 4th quarter. Legal & General Group Plc now owns 8,370 shares of the biopharmaceutical company’s stock worth $93,000 after purchasing an additional 945 shares in the last quarter. BNP Paribas Arbitrage SA boosted its position in shares of Omeros by 16,167.2% during the 1st quarter. BNP Paribas Arbitrage SA now owns 9,923 shares of the biopharmaceutical company’s stock worth $172,000 after purchasing an additional 9,862 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY boosted its position in shares of Omeros by 417.4% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 16,004 shares of the biopharmaceutical company’s stock worth $178,000 after purchasing an additional 12,911 shares in the last quarter. 51.72% of the stock is currently owned by institutional investors.

About Omeros

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

Further Reading: How is a Moving Average Calculated?

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit